KEAP1/NFE2L2突变预测肺癌放疗抵抗,谷氨酰胺酶抑制可靶向干预
该研究分析232例局限性非小细胞肺癌患者,发现KEAP1和NFE2L2突变可预测放疗后高局部复发率而非手术,约半数局部复发发生于携带这些突变的肿瘤。功能分析显示仅致病性突变与放疗抵抗相关,谷氨酰胺酶抑制通过耗竭谷胱甘肽优先使KEAP1突变细胞放疗增敏。
要点
- KEAP1/NFE2L2突变预测局限性NSCLC放疗后局部复发而非手术后。
- 约半数局部复发发生于携带KEAP1/NFE2L2突变的肿瘤。
- 谷氨酰胺酶抑制可优先使KEAP1突变细胞放疗增敏。
核心结论
- KEAP1/NFE2L2突变是局限性NSCLC放疗抵抗的主要分子驱动因素,谷氨酰胺酶抑制可能实现个性化放疗增敏。
研究设计与样本
- 分析232例连续性局限性NSCLC患者,并对放疗队列进行KEAP1/NFE2L2突变的功能评估。
主要发现
- KEAP1和NFE2L2突变预测放疗后高局部复发率而非手术后。
- 约半数局部复发发生于携带KEAP1/NFE2L2突变的肿瘤。
- 仅致病性KEAP1/NFE2L2突变与放疗抵抗相关。
- NFE2L2靶基因表达不能预测局部复发。
- 谷氨酰胺酶抑制通过耗竭谷胱甘肽和增加辐射诱导DNA损伤优先使KEAP1突变细胞放疗增敏。
关键数值与推荐
- 232例连续性局限性NSCLC患者中,KEAP1/NFE2L2突变预测放疗后高局部复发率而非手术后。
- 约半数局部复发发生于携带KEAP1/NFE2L2突变的肿瘤。
- 仅致病性KEAP1/NFE2L2突变与放疗抵抗相关。
- NFE2L2靶基因表达不能预测局部复发。
临床怎么用
- 对局限性NSCLC进行KEAP1/NFE2L2基因分型可能有助于治疗个性化。
- 谷氨酰胺酶抑制可能作为克服KEAP1/NFE2L2突变所致放疗抵抗的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tumor genotyping is not routinely performed in localized non-small cell lung cancer (NSCLC) due to lack of associations of mutations with outcome. Here, we analyze 232 consecutive patients with localized NSCLC and demonstrate that KEAP1 and NFE2L2 mutations are predictive of high rates of local recurrence (LR) after radiotherapy but not surgery. Half of LRs occurred in tumors with KEAP1/NFE2L2 mutations, indicating that they are major molecular drivers of clinical radioresistance. Next, we functionally evaluate KEAP1/NFE2L2 mutations in our radiotherapy cohort and demonstrate that only pathogenic mutations are associated with radioresistance. Furthermore, expression of NFE2L2 target genes does not predict LR, underscoring the utility of tumor genotyping. Finally, we show that glutaminase inhibition preferentially radiosensitizes KEAP1-mutant cells via depletion of glutathione and increased radiation-induced DNA damage. Our findings suggest that genotyping for KEAP1/NFE2L2 mutations could facilitate treatment personalization and provide a potential strategy for overcoming radioresistance conferred by these mutations. SIGNIFICANCE: This study shows that mutations in KEAP1 and NFE2L2 predict for LR after radiotherapy but not surgery in patients with NSCLC. Approximately half of all LRs are associated with these mutations and glutaminase inhibition may allow personalized radiosensitization of KEAP1/NFE2L2-mutant tumors.This article is highlighted in the In This Issue feature, p. 1775.
引用
- Binkley MS, Jeon YJ, Nesselbush M, et al. KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. Cancer Discov. 2020. PMID: 33071215. doi:10.1158/2159-8290.CD-20-0282
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。